Company Overview
| Stock Name | Mediwelcome |
|---|---|
| Stock Code | 02159 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 主要提供(i)醫學會議服務、(ii)患者教育及自測服務及(iii)營銷戰略和諮詢服務,目標為解決心腦血管疾病醫療生態系統各主要利益相關者的未滿足需求,並彌合該等利益相關者之間的距離。亦於2019年年底開始提供CRO服務及互聯網醫院服務。 |
| Listing Date | 2021-01-19 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市朝陽區東四環北路2號上東公園里10-12層 |
| Business Address (Hong Kong) | 香港禧利街27號富輝商業中心22樓2204室 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.mediwelcome.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 3.00 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 800 shares |
| Entry Threshold | HK$ 2,400 |
| Par Value | To be extracted |
| Offer Period | 2020-12-31 to 2021-01-08 |
| Global Offering Shares | 50,000,000 shares |
| HK Public Offer Shares (Initial) | 5,000,000 shares (10.0%) |
| Public Offer Lots (Initial) | 6,250lots (Pool A3,125lots,Pool B3,125lots) |
| International Placing Shares (Initial) | 45,000,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 200,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | No cornerstone investors |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 150,000,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 800 | HK$ 2,400 |
| 2 lots | 1,600 | HK$ 4,800 |
| 3 lots | 2,400 | HK$ 7,200 |
| 4 lots | 3,200 | HK$ 9,600 |
| 5 lots | 4,000 | HK$ 12,000 |
| 6 lots | 4,800 | HK$ 14,400 |
| 7 lots | 5,600 | HK$ 16,800 |
| 8 lots | 6,400 | HK$ 19,200 |
| 9 lots | 7,200 | HK$ 21,600 |
| 10 lots | 8,000 | HK$ 24,000 |
| 15 lots | 12,000 | HK$ 36,000 |
| 20 lots | 16,000 | HK$ 48,000 |
| 25 lots | 20,000 | HK$ 60,000 |
| 30 lots | 24,000 | HK$ 72,000 |
| 35 lots | 28,000 | HK$ 84,000 |
| 40 lots | 32,000 | HK$ 96,000 |
| 45 lots | 36,000 | HK$ 108,000 |
| 50 lots | 40,000 | HK$ 120,000 |
| 75 lots | 60,000 | HK$ 180,000 |
| 100 lots | 80,000 | HK$ 240,000 |
| 125 lots | 100,000 | HK$ 300,000 |
| 150 lots | 120,000 | HK$ 360,000 |
| 175 lots | 140,000 | HK$ 420,000 |
| 200 lots | 160,000 | HK$ 480,000 |
| 225 lots | 180,000 | HK$ 540,000 |
| 250 lots | 200,000 | HK$ 600,000 |
| 375 lots | 300,000 | HK$ 900,000 |
| 500 lots | 400,000 | HK$ 1,200,000 |
| 625 lots | 500,000 | HK$ 1,500,000 |
| 750 lots | 600,000 | HK$ 1,800,000 |
| 875 lots | 700,000 | HK$ 2,100,000 |
| 1,000 lots | 800,000 | HK$ 2,400,000 |
| 1,125 lots | 900,000 | HK$ 2,700,000 |
| 1,250 lots | 1,000,000 | HK$ 3,000,000 |
| 1,500 lots | 1,200,000 | HK$ 3,600,000 |
| 1,750 lots | 1,400,000 | HK$ 4,200,000 |
| 2,000 lots | 1,600,000 | HK$ 4,800,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 2,250 lots | 1,800,000 | HK$ 5,400,000 |
| 2,500 lots | 2,000,000 | HK$ 6,000,000 |
| 2,750 lots | 2,200,000 | HK$ 6,600,000 |
| 3,125 lots | 2,500,000 | HK$ 7,500,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 534.5M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1717% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 600,000,000 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣22.1百萬元 |
| Period-End Cash Balance | 人民幣73.6百萬元 |
| Listing Expenses | ~HK$ 64,200,000 |
| Listing Expenses / Funds Raised | ~42.8% |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2017 | 2018 | 2019 |
|---|---|---|---|
| Revenue | 258,880 | 298,968 | 427,159 |
| Cost of sales | -187,506 | -214,372 | -332,291 |
| Gross profit | 71,374 | 84,596 | 94,868 |
| Other income and gains, net | 573 | 2,290 | 3,339 |
| Selling and distribution expenses | -4,180 | -4,636 | -6,377 |
| Administrative expenses | -23,643 | -26,384 | -34,196 |
| Net finance costs | -268 | -301 | -309 |
| Profit before tax | 38,118 | 49,152 | 25,972 |
| Income tax expense | -7,902 | -9,475 | -3,915 |
| Profit for the year | 30,216 | 39,677 | 22,057 |
| Profit attributable to owners | 29,657 | 38,041 | 20,852 |
Balance Sheet
| Item | 2017 | 2018 | 2019 | 2020-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 90,219 | 99,205 | 73,642 | |
| Trade and bills receivables | 27,530 | 30,665 | 71,719 | |
| Total current assets | 129,348 | 142,284 | 179,896 | |
| Total assets | 140,256 | 203,173 | 229,481 | |
| Total current liabilities | 40,955 | 73,621 | 83,491 | |
| Total equity | 98,735 | 126,586 | 144,805 | |
| Equity attributable to owners | 93,939 | 118,907 | 135,921 | |
| Interest-bearing borrowings | 2,960 | 8,072 | 4,164 | 37,155 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019 | 2020-06 |
|---|---|---|---|---|
| Net cash from operating activities | -1,641 | 58,839 | 4,515 | |
| Net cash from investing activities | 2,460 | -30,383 | -24,523 | |
| Net cash from financing activities | 31,179 | -19,470 | -5,555 | |
| Net increase in cash | 31,998 | 8,986 | -25,563 | |
| Depreciation of PP&E | 2,879 | 2,652 | 2,666 | 1,406 |
| Depreciation of right-of-use assets | 5,262 | 5,434 | 5,352 | 3,000 |
| Amortisation of intangible assets | 81 | 221 | 2,711 | 3,336 |
| Purchase of PP&E | -3,138 | -3,131 | -2,138 | -3,450 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 3.79 |
|---|---|
| First Day Open | HK$ 4.0 |
| First Day Change | 26.33% |
| First Day Volume | 100586000.0 |
| First Day Turnover | 402943000.0 |
| Use of Proceeds | 1、估計總所得款項凈額約58%或51.8百萬港元用于拓展我們的客戶群、疾病覆蓋范圍及患者群;
2、估計總所得款項凈額約25%或22.3百萬港元用于發展我們的互聯網醫院服務;
3、估計總所得款項凈額約12%或10.7百萬港元用于運營資金及一般公司用途;
4、估計總所得款項凈額約5%或4.5百萬港元發展CRO服務,包括招募經驗豐富的員工團隊。 |
Underwriting Syndicate
Sole Sponsor (1)
CEB International Capital Corporation Limited CE BGH296
Joint Bookrunners (5)
Joint Lead Managers (7)
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 施煒 | — |
| Company Secretary | 趙魯陽、梁慧玲 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 施煒先生、楊為民先生、張藝濤女士及王亮先生為一致行動人士,透過各自全資公司(霽澤投資、舜嘉投資、禾匯萬怡投資、泰之豐投資)共同持有103,519,000股,緊隨全球發售完成後約佔51.76%。RSU Holdings持有20,000,000股,約10.0%。 |
|---|




